Researchers at the University of Cambridge have developed a novel immunotherapeutic approach that activates the STING pathway, an innate immune sensor, to enhance immune defenses against cancer. This strategy improves both the precision and safety of cancer treatments by orchestrating potent antitumor immune responses. The findings represent a significant advancement in immunotherapy, potentially enabling more effective therapies with fewer adverse effects.